Lymphoma Needs Assessment Survey

Elsevier Office of Continuing Medical Education and In Vivo Academy are developing a continuing medical education (CME) activity to support clinicians in making informed decisions about diagnostic tests and treatment choice in lymphoma based on accurate statistical interpretation of clinical trial results. The following survey, which will take less than 10 minutes to complete, aims to gain a comprehensive picture of your unmet educational needs in this area. Please help us identify priorities in developing the CME activity by completing the survey.

Are you a medical professional? *

Yes

What is your main medical specialty? *

Haematology

Medical oncology

Radiation oncology

Nuclear medicine

Radiation/Imaging

Surgery

General Practice

Endocrinology

Other

What is your main medical specialty? Other

Degree (Please choose all that apply) Other

Your current professional practice: *

Private hospital/practice

Public hospital

Academic research

How many patients with lymphoma do you typically see in one month? *

A patient receives a positive result for a test to detect a particular condition. The test is known to have a false positive rate of 5% and the prevalence of the particular condition in the population is known to be 1 in 1000 people. What is the chance that this particular patient actually has the condition tested for? *

Which of the following statements about surrogate endpoints is FALSE? *

A surrogate endpoint need not be responsive to the effects of treatment

Objective response rate and progression free survival are surrogate endpoints commonly used in oncological trials

Use of a surrogate, if correlated imprecisely with definitive endpoints, can lead to misleading results

Surrogate endpoints can shorten the length and increase the efficiency of clinical trials

Overall survival (OS) is the only appropriate indicator of treatment efficacy *

Overall survival (OS) is the only appropriate indicator of treatment efficacy Depends (please specify)

I am confident about my understanding of the statistical concepts and endpoints used in clinical studies evaluating the efficacy and safety of therapies *

I am confident about my understanding of the statistical concepts and endpoints used in clinical studies evaluating the efficacy and safety of therapies Depends (please specify)

I communicate with my patients the significance of clinical trial results and the meaning of endpoints and how these will affect their disease state, quality of life and overall survival *

I communicate with my patients the significance of clinical trial results and the meaning of endpoints and how these will affect their disease state, quality of life and overall survival Depends (please specify)

I ensure that the treatment choice is aligned with my patient’s expectation from the treatment (better quality of life, prolonged survival etc.) *

I ensure that the treatment choice is aligned with my patient’s expectation from the treatment (better quality of life, prolonged survival etc.) Depends (please specify)

How confident are you about your knowledge of the advantages and limitations of the following endpoints/surrogate endpoints as a guide to treatment choice in various patient populations (e.g. treatment naïve patients, patients who have relapsed or are refractory to treatment, patients whose lymphoma has transformed from indolent to aggressive)? *

	Very confident	Confident	Somewhat confident	Not at all confident
Overall survival (OS)	Overall survival (OS) - Very confident	Overall survival (OS) - Confident	Overall survival (OS) - Somewhat confident	Overall survival (OS) - Not at all confident
Progression free survival (PFS)	Progression free survival (PFS) - Very confident	Progression free survival (PFS) - Confident	Progression free survival (PFS) - Somewhat confident	Progression free survival (PFS) - Not at all confident
Event free survival (EFS)	Event free survival (EFS) - Very confident	Event free survival (EFS) - Confident	Event free survival (EFS) - Somewhat confident	Event free survival (EFS) - Not at all confident
Time to next treatment (TTNT)	Time to next treatment (TTNT) - Very confident	Time to next treatment (TTNT) - Confident	Time to next treatment (TTNT) - Somewhat confident	Time to next treatment (TTNT) - Not at all confident
Time to progression (TTP)	Time to progression (TTP) - Very confident	Time to progression (TTP) - Confident	Time to progression (TTP) - Somewhat confident	Time to progression (TTP) - Not at all confident
Progression of disease in 24 months (POD24)	Progression of disease in 24 months (POD24) - Very confident	Progression of disease in 24 months (POD24) - Confident	Progression of disease in 24 months (POD24) - Somewhat confident	Progression of disease in 24 months (POD24) - Not at all confident
Progression free survival in 24 months (PFS24)	Progression free survival in 24 months (PFS24) - Very confident	Progression free survival in 24 months (PFS24) - Confident	Progression free survival in 24 months (PFS24) - Somewhat confident	Progression free survival in 24 months (PFS24) - Not at all confident
Minimal residual disease (MRD)	Minimal residual disease (MRD) - Very confident	Minimal residual disease (MRD) - Confident	Minimal residual disease (MRD) - Somewhat confident	Minimal residual disease (MRD) - Not at all confident
Complete response at 30 months (CR30)	Complete response at 30 months (CR30) - Very confident	Complete response at 30 months (CR30) - Confident	Complete response at 30 months (CR30) - Somewhat confident	Complete response at 30 months (CR30) - Not at all confident

Which of the following topics, if any, of an educational activity on lymphoma would you consider beneficial to you? Please tick all that apply. *

Advantages and limitations of endpoints and surrogate endpoints used in clinical trials of lymphoma therapy

An evaluation of new and existing therapies

Use and interpretation of statistics in clinical settings

Other (please specify)

Which of the following topics, if any, of an educational activity on lymphoma would you consider beneficial to you? Please tick all that apply. Other (please specify)

If we are to provide you with an educational resource (e.g. reading materials, videos, online modules) that you can access/download after the CME activity, would you most likely: *

Use the materials for personal improvement and reinforcement of what you learned in the activity

Share them with colleagues for their own use

Use the materials to train members of your clinical team (e.g. nurses/nurse counsellors, radiotherapists, diagnostic radiologists)

Not use them at all

Following the completion of this survey we are keen to interview participants to better understand the educational gaps. If you are willing to be interviewed for no more than 15 minutes, please type in your name and contact details:

Name:

Email Address:

Phone Number:

Skype ID/WhatsApp etc.:

Availability:

Thank you for your interest in this survey. Unfortunately at this time, you do not qualify to participate in this survey.

Leave this field blank

You are here

Lymphoma Needs Assessment Survey